The 39th David A. Karnofsky Lecture: bench-to-bedside translation of targeted therapies in multiple myeloma.
about
Targeted Therapies in Adult B-Cell MalignanciesNovel agents for multiple myeloma to overcome resistance in phase III clinical trialsInhibition of the MDM2 E3 Ligase induces apoptosis and autophagy in wild-type and mutant p53 models of multiple myeloma, and acts synergistically with ABT-737Phase 1 study of weekly dosing with the investigational oral proteasome inhibitor ixazomib in relapsed/refractory multiple myeloma.The novel immunotoxin HM1.24-ETA' induces apoptosis in multiple myeloma cells.New strategies in the treatment of multiple myeloma.A novel TLR-9 agonist C792 inhibits plasmacytoid dendritic cell-induced myeloma cell growth and enhance cytotoxicity of bortezomib.New insights into the treatment of multiple myeloma with histone deacetylase inhibitors.Chromatin structure, transcriptional activity and DNA repair efficiency affect the outcome of chemotherapy in multiple myeloma.Novel approaches to treatment of double-refractory multiple myeloma.Novel therapeutics in multiple myeloma.Overview of proteasome inhibitor-based anti-cancer therapies: perspective on bortezomib and second generation proteasome inhibitors versus future generation inhibitors of ubiquitin-proteasome system.Targeting the pro-survival protein MET with tivantinib (ARQ 197) inhibits growth of multiple myeloma cells.Anti-CD138-targeted interferon is a potent therapeutic against multiple myeloma.Profile of elotuzumab and its potential in the treatment of multiple myelomaTherapeutic landscape of carfilzomib and other modulators of the ubiquitin-proteasome pathway.Synergistic anti-myeloma activity of the proteasome inhibitor marizomib and the IMiD immunomodulatory drug pomalidomide.Model of translational cancer research in multiple myeloma.Multiple Myeloma: Treatment is Getting IndividualizedNelfinavir augments proteasome inhibition by bortezomib in myeloma cells and overcomes bortezomib and carfilzomib resistance.Minimal effect of bortezomib in reducing anti-pig antibodies in human leukocyte antigen-sensitized patients: a pilot study.European Myeloma Network recommendations on the evaluation and treatment of newly diagnosed patients with multiple myeloma.Panobinostat synergizes with zoledronic acid in prostate cancer and multiple myeloma models by increasing ROS and modulating mevalonate and p38-MAPK pathways.A preclinical model of CD38-pretargeted radioimmunotherapy for plasma cell malignancies.Exocytosis of polyubiquitinated proteins in bortezomib-resistant leukemia cells: a role for MARCKS in acquired resistance to proteasome inhibitors.Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients.Inhibitors for the immuno- and constitutive proteasome: current and future trends in drug development.Association of response endpoints with survival outcomes in multiple myeloma.Desensitization in kidney transplantation: review and future perspectives.Understanding biology to tackle the disease: Multiple myeloma from bench to bedside, and back.The investigational proteasome inhibitor ixazomib for the treatment of multiple myeloma.Emerging antibody-drug conjugates for treating lymphoid malignancies.Mechanisms and Clinical Applications of Genome Instability in Multiple Myeloma.Long-term disease control in a refractory multiple myeloma patient treated with bortezomib mono-therapy: a case report and review of literature.Management of Multiple Myeloma with Second-Generation Antibody-Drug Conjugates.DNA repair of myeloma plasma cells correlates with clinical outcome: the effect of the nonhomologous end-joining inhibitor SCR7.A retrospective analysis of 3954 patients in phase 2/3 trials of bortezomib for the treatment of multiple myeloma: towards providing a benchmark for the cardiac safety profile of proteasome inhibition in multiple myeloma.MiR-301a promotes cell proliferation by directly targeting TIMP2 in multiple myeloma.RECQ1 helicase is involved in replication stress survival and drug resistance in multiple myelomaManagement of adverse events induced by next-generation immunomodulatory drug and proteasome inhibitors in multiple myeloma.
P2860
Q26783195-1E61C19E-1394-4BF1-9B9A-4B76FAD715D8Q26822754-40CFB0F0-7E7D-4FAE-B444-F1753F6F5F62Q28542684-3CB9362B-1C98-45C1-B6DD-8F2169C6CDBBQ33415759-BB1D72DA-7349-489B-BD85-8DD750B31F5CQ33840201-98DFC2DD-AE4E-45F7-B3C9-857A74C3FB4BQ33958520-D5330394-C4B8-4CC9-877D-05C2F8C1B34CQ33976734-C9F824F1-619F-4538-BB36-E8078EE92B93Q34224278-3E970E79-53DC-496C-91E2-08AD9FA72058Q34283680-D968253D-175D-45F9-8C8A-CCFBA00CDB39Q34347172-F8CA7B6E-0143-4F36-A21F-A1FC1F71C7D8Q34637538-999266BD-1020-40A7-8401-B1034301C345Q34788381-19C9CE71-2E63-4FEB-A055-DBD7F5889A83Q35214544-1EA1C3D9-A7A2-4EAB-9761-654B6AFC72F9Q35321868-5F62FACF-1B2E-4D6A-8897-E92C7D382EBDQ35628678-2F029700-7802-4F51-AB12-32724421531FQ35895152-0B1A6BC2-3259-460C-93FD-FC76F33BF3CDQ36470302-8DBD1BDF-1751-470D-8934-593E4C957D6CQ36498784-6637FD2D-AAE8-44EF-9CDA-40D85352F6BBQ36522964-A430814A-3422-4898-8FF3-B679AFF5D522Q36736534-38937145-B366-4395-B223-913B73611F0DQ37361071-7FB3A796-D5C6-4D65-9645-A3D86888AF82Q37552008-FA5DFEC4-DB28-45CC-A5D2-3A23C4AADA2DQ37577433-20009D99-100E-4C74-9207-5634646F678FQ37675882-5865DA70-1F8E-4D68-8A25-02ABBD4DB31EQ37688848-867E3A64-5A53-4C6C-B924-59584E5DDD06Q37724272-4A263C48-D021-4FFD-BE9E-E1223401D2ECQ38019864-9B947B61-46E7-412D-A043-C1802B79825DQ38122624-F257C15E-88A8-46DE-90CE-DC94DD3A1370Q38195324-D4003215-F317-4572-8A76-3DE70BF7A1F4Q38255333-209562EA-F961-43C6-8247-B5713F26CD9BQ38400460-03F22F5B-5F85-492D-BA23-B321F514B919Q38632313-AFEC9C4D-3C07-4F59-9D5D-8E5755880F7CQ38637046-710B4685-140E-43DA-AB01-B2CA986E29E0Q38697604-99F74D20-9BAF-4104-8B97-F75CEDADAA4DQ38755443-573A7433-B44C-4C26-BED9-778026B12A51Q38756630-53E6CF0E-DB72-4651-B4A4-4B944EA8A75CQ38807562-319A52E8-9CF1-43E5-989F-7185273BF456Q38828052-F2CB322A-E51D-458D-84AF-9103695C91A6Q38967891-FDB1AA86-81DE-4E0C-B16D-6ABA5B0DCD83Q39022303-F4949C83-2A3C-4269-A5BF-5D928BF30C1F
P2860
The 39th David A. Karnofsky Lecture: bench-to-bedside translation of targeted therapies in multiple myeloma.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
The 39th David A. Karnofsky Le ...... therapies in multiple myeloma.
@ast
The 39th David A. Karnofsky Le ...... therapies in multiple myeloma.
@en
type
label
The 39th David A. Karnofsky Le ...... therapies in multiple myeloma.
@ast
The 39th David A. Karnofsky Le ...... therapies in multiple myeloma.
@en
prefLabel
The 39th David A. Karnofsky Le ...... therapies in multiple myeloma.
@ast
The 39th David A. Karnofsky Le ...... therapies in multiple myeloma.
@en
P2860
P356
P1476
The 39th David A. Karnofsky Le ...... therapies in multiple myeloma.
@en
P2093
Kenneth C Anderson
P2860
P304
P356
10.1200/JCO.2011.37.8919
P407
P577
2012-01-03T00:00:00Z